160 related articles for article (PubMed ID: 34659755)
1. Severe Symptomatic Hypocalcemia, complicating cardiac arrhythmia following Cinacalcet (Sensipar
Schmidt GS; Weaver TD; Hoang TD; Shakir MKM
Clin Case Rep; 2021 Oct; 9(10):e04876. PubMed ID: 34659755
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes.
Louie KS; Erhard C; Wheeler DC; Stenvinkel P; Fouqueray B; Floege J
J Nephrol; 2020 Aug; 33(4):803-816. PubMed ID: 31848883
[TBL] [Abstract][Full Text] [Related]
3. Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial.
Floege J; Tsirtsonis K; Iles J; Drueke TB; Chertow GM; Parfrey P
Kidney Int; 2018 Jun; 93(6):1475-1482. PubMed ID: 29525393
[TBL] [Abstract][Full Text] [Related]
4. Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism.
Di Dalmazi G; Giuliani C; Napolitano G
Front Endocrinol (Lausanne); 2018; 9():777. PubMed ID: 30622514
[TBL] [Abstract][Full Text] [Related]
5. [Basic and clinical aspects of calcimimetics. The clinical effect and usefulness of Cinacalcet as a calcimimetics on three CKD-5D patients undergoing hemodialysis with refractory secondary hyperparathyroidism].
Hanba Y; Ooura M; Negi S; Shigematsu T
Clin Calcium; 2008 Jan; 18(1):81-8. PubMed ID: 18175876
[TBL] [Abstract][Full Text] [Related]
6. Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis.
Zhang Q; Li M; You L; Li H; Ni L; Gu Y; Hao C; Chen J
PLoS One; 2012; 7(10):e48070. PubMed ID: 23133549
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet-induced hungry bone syndrome.
Lazar ES; Stankus N
Semin Dial; 2007; 20(1):83-5. PubMed ID: 17244128
[TBL] [Abstract][Full Text] [Related]
8. Facing cinacalcet-induced hypocalcemia: sit back and relax?
Evenepoel P; Shroff R
Kidney Int; 2018 Jun; 93(6):1275-1277. PubMed ID: 29792272
[TBL] [Abstract][Full Text] [Related]
9. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.
Lomonte C; Antonelli M; Losurdo N; Marchio G; Giammaria B; Basile C
Nephrol Dial Transplant; 2007 Jul; 22(7):2056-62. PubMed ID: 17449495
[TBL] [Abstract][Full Text] [Related]
10. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.
Finch JL; Tokumoto M; Nakamura H; Yao W; Shahnazari M; Lane N; Slatopolsky E
Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1315-22. PubMed ID: 20200094
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism.
Sterrett JR; Strom J; Stummvoll HK; Bahner U; Disney A; Soroka SD; Corpier C; Arruda JA; Schwanauer LE; Klassen PS; Olson KA; Block GA
Clin Nephrol; 2007 Jul; 68(1):10-7. PubMed ID: 17703830
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet hydrochloride: calcimimetic for the treatment of hyperparathyroidism.
Locatelli F; Pontoriero G; Limardo M; Tentori F
Expert Rev Endocrinol Metab; 2006 Mar; 1(2):167-179. PubMed ID: 30754140
[TBL] [Abstract][Full Text] [Related]
13. Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring.
Nowack R; Wachtler P
Clin Lab; 2006; 52(11-12):583-7. PubMed ID: 17175888
[TBL] [Abstract][Full Text] [Related]
14. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.
Bover J; Ureña P; Ruiz-García C; daSilva I; Lescano P; del Carpio J; Ballarín J; Cozzolino M
Clin J Am Soc Nephrol; 2016 Jan; 11(1):161-74. PubMed ID: 26224878
[TBL] [Abstract][Full Text] [Related]
16. The Effectiveness of Cinacalcet as an Adjunctive Therapy for Hereditary 1,25 Dihydroxyvitamin D3-Resistant Rickets.
Akıncı A; Dündar İ; Kıvılcım M
J Clin Res Pediatr Endocrinol; 2017 Jun; 9(2):172-178. PubMed ID: 27796266
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet-Associated Resolution of Primary Hyperparathyroidism in a Patient With Normal Kidney Function.
Nguyen S; Gosmanova EO; Gosmanov AR
J Investig Med High Impact Case Rep; 2020; 8():2324709620936836. PubMed ID: 32583691
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
Warady BA; Iles JN; Ariceta G; Dehmel B; Hidalgo G; Jiang X; Laskin B; Shahinfar S; Vande Walle J; Schaefer F
Pediatr Nephrol; 2019 Mar; 34(3):475-486. PubMed ID: 30506144
[TBL] [Abstract][Full Text] [Related]
20. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
